ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer

Shi, Xiaoshun; Dong, Xiaoying; Zhai, Jianxue; Liu, Xiguang; Lu, Di; Ni, Zhen; Wu, Hua; Cai, Kaican*南方医科大学
Frontiers in Oncology2021-5-24DOI: 10.3389/fonc.2021.608608
5被引7阅读
引用收藏
分享

摘要

Purpose @@@ Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been indicated to be an effective treatment for advanced EGFR-mutant NSCLC. However, the neoadjuvant application of EGFR-TKIs in resectable NSCLC needs further investigation. Here, we aimed to evaluate the efficacy and safety of neoadjuvant EGFR-TKIs for lung cancer. @@@ Methods @@@ Published studies on neoadjuvant EGFR-TKIs in NSCLC were identified in PubMed, Web of Science, and EMBASE until June 1, 2020. Data on surgical rates, objective response rates (ORRs), pathologic responses, and adverse event (AE) rates were retrieved for proportional meta-analysis. @@@ Results @@@ In total, 7 enrolled studies involving 129 EGFR-TKI-sensitive NSCLC patients were included in this analysis. The overall surgical rate in these studies was 95% (95% CI: 83% to 100%), with an ORR of 48% (95% CI: 39% to 57%) in the population with EGFR-TKI-sensitive mutations, whereas the ORR including wild-type EGFR patients was 28% (95% CI: 14% to 44%). The rate of grade 1-2 AEs was 69% (95% CI: 41% to 91%) but with an acceptable rate of grade 3-4 AEs of 0% (95% CI: 0% to 5%). The pooled rates of rash and diarrhea were 56% (95% CI: 31% to 79%) and 25% (95% CI: 6% to 51%), respectively. The impact of neoadjuvant EGFR-TKIs on survival remains inconclusive. @@@ Conclusions @@@ Neoadjuvant EGFR-TKIs showed objective responses in approximately half of EGFR-sensitive NSCLC patients with a tolerable adverse effect profile. The favorable impact of neoadjuvant EGFR-TKIs on NSCLC needs more evidence for validation, such as the comparison of survival improvement between EGFR-TKIs and chemotherapy. The efficacy of neoadjuvant next-generation EGFR-TKIs in clinical trials remains unclear.

学科与关键词

关键词
neoadjuvant therapyEGFR-TKImeta-analysisNSCLCsurgery
相关
加载中…
  • Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial
    Lv, Chao; Fang, Wentao; Wu, Nan; Jiao, Wenjie; Xu, Shidong; Ma, Haitao; Wang, Jia; Wang, Rui; Ji, Chunyu; Li, Shaolei; Wang, Yuzhao; Yan, Shi; Lu, Fangliang; Pei, Yuquan; Liu, Yinan; Yang, Yue*Lung Cancer, 2023, 178: 151-156.被引 10
  • Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer
    Zhou, Jia-Ying; Liu, Si-Yang; Wu, Yi-Long*Expert Opinion On Drug Safety, 2020, 19(5): 589-599.被引 12
  • Case report: an initially unresectable stage III pulmonary sarcomatoid carcinoma qith EGFR mutation achieving pathological complete response following neoadjuvant therapy with osimertinib plus chemotherapy
    Liu, Xiguang; Zheng, Yating; Mai, Shijie; Tong, Yu; Yang, Lili; Huang, Mengli; Cai, Ruijun*Frontiers in Oncology, 2022, 12: 1033322.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2021-05-24
卷期
第 11 卷
页码
608608
DOI
10.3389/fonc.2021.608608
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
Research Initiative Fund of Southern Hospital [C1051325]; National Natural Science Foundation of China [81902319]; Major Science and Technology Planning Project of Guangdong Province [2017B020226005]; Science and Technology Program of Guangzhou City [201903010003]

作者

  • S

    Shi, Xiaoshun (第一作者)

    southern med univ

  • D

    Dong, Xiaoying

    southern med univ

查看全部 8 位作者收起作者
  • Z

    Zhai, Jianxue

    southern med univ

  • L

    Liu, Xiguang

    southern med univ

  • L

    Lu, Di

    southern med univ

  • N

    Ni, Zhen

    southern med univ

  • W

    Wu, Hua

    southern med univ

  • C

    Cai, Kaican (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417